Novo Nordisk A/S (NVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $183.52B
Last updated: Nov 17, 2026 at 5:28 PM ET
Novo Nordisk A/S (NVO) Statistics
Novo Nordisk A/S (NVO) has a market cap of $183.52B. Its dividend yield is 4.41%. Its return on invested capital of 34.13% compares with a 12.84% median across 11 similar companies.
Total Valuation
| Market Cap | $183.52B |
|---|---|
| Latest price (Nov 17, 2026) | $40.70 |
Key Dates
The last ex-dividend date was Aug 17, 2026.
| Last Earnings Date | Nov 4, 2026 |
|---|---|
| Last Ex-Dividend Date | Aug 17, 2026 |
| Last Payment Date | Aug 25, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 3.5x and 5.4x. Its year-end P/S ranged from 4.7x to 13.8x from 2016 to 2025.
| P/S Ratio | 3.5x |
|---|---|
| P/B Ratio | 5.4x |
| P/TBV Ratio | 11.2x |
| P/FCF Ratio | 26.0x |
Enterprise Valuation
Counting debt and cash, the company is valued at 6.8x EBITDA and 28.0x free cash flow.
| EV / EBITDA | 6.8x |
|---|---|
| EV / FCF | 28.0x |
Price Statistics
The stock is down 12.75% over 52 weeks and trades 2.01% above its 50-day average.
| Beta (1Y) | 0.95 |
|---|---|
| 52-Week Change | -12.75% |
| 1-Month Change | +5.95% |
| 3-Month Change | -12.42% |
| 6-Month Change | -6.89% |
| 5-Year Change | -27.36% |
| 10-Year Change | +125.10% |
| Total Return (1Y) | -8.89% |
| Total Return (3Y CAGR) | -24.45% |
| Total Return (5Y CAGR) | -4.82% |
| Return vs SPY (1Y) | -23.00% |
| Max Drawdown (1Y) | -44.39% |
| Max Drawdown (3Y) | -75.03% |
| Sharpe Ratio (1Y) | -0.26 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $39.90 |
| 200-Day Average | $42.46 |
| 52-Week Range | $34.15 to $61.11 |
| RSI (14 Days) | 52.1 |
| Average Volume (20 Days) | 12.27M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.84x current liabilities, and total debt is 0.62x shareholder equity.
| Current Ratio | 0.84x |
|---|---|
| Quick Ratio | 0.64x |
| Debt / Equity | 0.62x |
| Debt / EBITDA | 0.72x |
| Interest Coverage | 10.13x |
Returns and Efficiency
Return on invested capital is 34.13% over the last 12 months, against a 5-year average of 46.41%.
| Return on Equity (ROE) | 52.96% |
|---|---|
| Return on Assets (ROA) | 19.25% |
| Return on Invested Capital (ROIC) | 34.13% |
| Return on Capital Employed (ROCE) | 43.12% |
| ROE (5Y Average) | 67.14% |
| ROA (5Y Average) | 22.95% |
| ROIC (5Y Average) | 46.41% |
| Asset Turnover | 0.60x |
| Inventory Turnover | 1.26x |
| Receivables Turnover | 3.26x |
| Cash Conversion Cycle | -79 days |
Taxes
Income tax took 21.77% of pretax income over the last 12 months.
| Income Tax (TTM) | DKK 31.49B |
|---|---|
| Effective Tax Rate | 21.77% |
Scores
NVO has an Altman Z-Score of 3.72, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.72 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of DKK 333.65B over the last 12 months is up 5.72% from the 12 months before.
| Revenue | DKK 333.65B |
|---|---|
| Revenue Growth (YoY) | +5.72% |
| Gross Profit | DKK 269.57B |
| Operating Income | DKK 141.43B |
| Pretax Income | DKK 144.67B |
| Net Income | DKK 113.18B |
| EBITDA | DKK 184.57B |
| EBIT | DKK 150.80B |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 36.35% of the DKK 599.16B in total assets.
| Working Capital | DKK -38.68B |
|---|---|
| Shareholder Equity | DKK 217.80B |
| Tangible Book Value | DKK 106.03B |
| Total Assets | DKK 599.16B |
| Total Liabilities | DKK 381.36B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After DKK 81.82B of capital spending, operating cash flow left DKK 46.32B of free cash flow.
| Operating Cash Flow | DKK 128.15B |
|---|---|
| Capital Expenditures | DKK 81.82B |
| Free Cash Flow | DKK 46.32B |
| Depreciation and Amortization | DKK 33.77B |
| Dividends Paid | DKK 52.02B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 42.39%, against a 5-year average of 42.72%.
| Gross Margin | 80.79% |
|---|---|
| Operating Margin | 42.39% |
| Pretax Margin | 43.36% |
| Net Margin | 33.92% |
| EBITDA Margin | 55.32% |
| EBIT Margin | 45.20% |
| FCF Margin | 13.88% |
| Gross Margin (5Y Average) | 83.47% |
| Operating Margin (5Y Average) | 42.72% |
| Net Margin (5Y Average) | 33.85% |
Growth
Revenue grew 20.43% a year over 3 years.
| Revenue Growth (3Y CAGR) | +20.43% |
|---|---|
| Revenue Growth (5Y CAGR) | +19.48% |
| FCF Growth (3Y CAGR) | -23.26% |
| FCF Growth (5Y CAGR) | -0.60% |
| Operating Income Growth (3Y CAGR) | +19.50% |
Dividends and Yields
NVO pays out 40.47% of earnings as dividends.
| Dividend Per Share (Annual) | $1.80 |
|---|---|
| Dividend Yield | 4.41% |
| Payment Schedule | Semi-Annual |
| Dividend Growth (3Y CAGR) | +29.23% |
| Dividend Growth (5Y CAGR) | +21.57% |
| Payout Ratio | 40.47% |
| FCF Payout Ratio | 115.78% |
| FCF Yield | 3.84% |
Stock Splits
The last split was a 2-for-1 forward split on Sep 20, 2023.
| Last Split Date | Sep 20, 2023 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 12 similar companies, NVO has the 9th highest P/S and the 3rd highest dividend yield.
P/S RatioPeer median 4.9x
ROICPeer median 12.84%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.71%
Dividend YieldPeer median 2.37%
| P/S Ratio | 3.5x vs 4.9x median |
|---|---|
| ROIC | 34.13% vs 12.84% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +5.72% vs +5.71% median |
| Dividend Yield | 4.41% vs 2.37% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NVO
What is NVO's market cap?
Novo Nordisk A/S has a market cap of $183.52B.
How many shares of NVO are outstanding?
Novo Nordisk A/S has 4.42B shares outstanding. The count is down 0.67% from a year earlier.
Does NVO pay a dividend?
Yes. Novo Nordisk A/S pays $1.80 a share a year, a dividend yield of 4.41%.
NVO pages: Overview, Dividends, Charting, Financials, Statistics, Valuation, Competitors